Optum Lifesciences on Muck Rack

Optum Lifesciences

As seen in: Value in Health Journal
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Optum

Contact Optum, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

EE189 HEALTHCARE RESOURCE UTILIZATION AND COSTS AMONG OVERACTIVE BLADDER PATIENTS WITH AND WITHOUT URINARY INCONTINENCE: A U.S. CLAIMS-BASED ANALYSIS

|
By Vikash Verma, Optum Lifesciences, Louis Brooks
| Value in Health Journal Verified
Overactive bladder (OAB) is a chronic condition characterized by urinary urgency, frequency, and nocturia, often accompanied by urinary incontinence (UI), which can significantly impact quality of life and healthcare costs. This study quantified healthcare resource utilization (HCRU) and costs among patients with urgency UI (UUI), stress UI (SUI), or mixed UI (MUI) in the context of OAB and assessed demographic and economic disparities to inform targeted interventions.
Open in Who Shared Issue with article?

CO178 COMPARATIVE EFFECTIVENESS OF RADIOLIGAND THERAPY IN PSMA-POSITIVE MCRPC: INSIGHTS FROM REAL-WORLD DATA

|
By Optum Lifesciences
| Value in Health Journal Verified
Cookie Preference Center We use cookies which are necessary to make our site work. We may also use additional cookies to analyse, improve and personalise our content and your digital experience. For more information, see our Cookie Policy and the list of Google Ad-Tech Vendors. You may choose not to allow some types of cookies. However, blocking some types may impact your experience of our site and the services we are able to offer.
Open in Who Shared View Duplicates (615) Issue with article?

CO48 REAL-WORLD COMPARATIVE OUTCOMES AND COSTS OF SGLT-2 INHIBITORS VERSUS DPP-4 INHIBITORS IN TYPE 2 DIABETES PATIENTS WITH HEART FAILURE

|
By Optum Lifesciences
| Value in Health Journal Verified
Cookie Preference Center We use cookies which are necessary to make our site work. We may also use additional cookies to analyse, improve and personalise our content and your digital experience. For more information, see our Cookie Policy and the list of Google Ad-Tech Vendors. You may choose not to allow some types of cookies. However, blocking some types may impact your experience of our site and the services we are able to offer.
Open in Who Shared View Duplicates (117) Issue with article?
See all 12 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified